Compositions and methods for treating viral infections through stimulated innate immunity in combination with antiviral compounds

Abstract

Embodiments are directed to compositions and methods for treating viral infections.

1 . A composition comprising: (a) lipopeptide, (b) immune stimulatory oligodeoxy nucleotide, and (c) antiviral pharmaceutical. 
     
     
         2 . The composition of  claim 1 , wherein the lipopeptide is PAM 2 CSK 4 . 
     
     
         3 . The composition of  claim 1 , wherein the immune stimulatory oligodeoxynucleotide is a type C oligodeoxynucleotide (ODN). 
     
     
         4 . The composition of  claim 3 , wherein the immune stimulatory oligodeoxynucleotide is ODN2395 or ODNM362 or ODN10101. 
     
     
         5 . The composition of  claim 1 , wherein the antiviral pharmaceutical is oseltamivir or ribavirin. 
     
     
         6 . The composition of  claim 1 , wherein the composition is formulated for administration to the lungs. 
     
     
         7 . A method of treating, inhibiting, or attenuating a viral infection comprising administering an effective amount of the composition of  claim 1  to an individual that has or is at risk of viral infection. 
     
     
         8 . The method of  claim 7 , wherein the subject has been exposed to a virus. 
     
     
         9 . The method of  claim 7 , wherein the virus is a Adenoviridae, Coronaviridae, Filoviridae, Flaviviridae, Hepadnaviridae, Herpesviridae, Orthomyxoviridae, Paramyxovirinae, Pneumovirinae, Picomaviridae, Poxyiridae, Retroviridae, or Togaviridae. 
     
     
         10 . The method of  claim 7 , wherein the virus is Parainfluenza, Influenza, H5N1, Marburg, Ebola, Severe acute respiratory syndrome coronavirus (SARS-COV), Middle eastern respiratory syndrome coronavirus (MERS-COV), yellow fever virus, human respiratory syncytial, Hantavirus, or Vaccinia virus. 
     
     
         11 . The method of  claim 7 , wherein the composition is administered by nebulization. 
     
     
         12 . The method of  claim 7 , wherein the lipopeptide, immune stimulatory oligonucleotide and anti-viral drug are administered in an amount of from about 0.1 mg/kg to about 100 mg/kg of the individual's body weight. 
     
     
         13 . A method of treating, inhibiting, or attenuating a viral infection comprising administering an effective amount of the composition comprising an aerosolized (a) lipopeptide and (b) immune stimulatory oligodeoxy nucleotide in combination with a composition comprising an anti-viral pharmaceutical to an individual that has or is at risk of viral infection. 
     
     
         14 . The method of  claim 13 , wherein the lipopeptide is PAM 2 CSK 4  and wherein the immune stimulatory oligodeoxynucleotide is ODN2395 or ODNM362 or ODN10101. 
     
     
         15 . The method of  claim 13 , wherein the immune stimulatory oligodeoxynucleotide is a type C oligodeoxynucleotide (ODN). 
     
     
         16 . (canceled) 
     
     
         17 . The method of  claim 13 , wherein the antiviral pharmaceutical is oseltamivir or ribavirin. 
     
     
         18 - 19 . (canceled) 
     
     
         20 . The composition of  claim 1 , wherein the composition is formulated for nebulization. 
     
     
         21 . A nebulizer comprising (a) lipopeptide, (b) immune stimulatory oligodeoxy nucleotide, and (c) anti-viral pharmaceutical. 
     
     
         22 - 25 . (canceled) 
     
     
         26 . The composition of  claim 1 , wherein the composition comprises 16 μM lipopeptide and 4 μM immune stimulatory oligodeoxy nucleotide. 
     
     
         27 . The composition of  claim 1 , wherein the molar ratio of lipopeptide to immune stimulatory oligodexy nucleotide is 4:1.